Opus Genetics, Inc. (IRD)vsRevolution Medicines Inc (RVMD)
IRD
Opus Genetics, Inc.
$3.85
+1.32%
HEALTHCARE · Cap: $336.94M
RVMD
Revolution Medicines Inc
$221.15
+2.65%
HEALTHCARE · Cap: $47.40B
Smart Verdict
WallStSmart Research — data-driven comparison
Opus Genetics, Inc. generates 1228% more annual revenue ($9.86M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs 0.0%. RVMD earns a higher WallStSmart Score of 24/100 (F).
IRD
Avoid19
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+29.1%
Fair Value
$4.64
Current Price
$3.85
$0.79 discount
Intrinsic value data unavailable for RVMD.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : IRD
The strongest argument for IRD centers on Debt/Equity.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : IRD
The primary concerns for IRD are EPS Growth, Market Cap, Profit Margin.
Bear Case : RVMD
The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.
Key Dynamics to Monitor
RVMD carries more volatility with a beta of 1.40 — expect wider price swings.
IRD is growing revenue faster at -73.8% — sustainability is the question.
IRD generates stronger free cash flow (-12M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
RVMD scores higher overall (24/100 vs 19/100). IRD offers better value entry with a 29.1% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Opus Genetics, Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Opus Genetics, Inc. (IRD) is a pioneering biotechnology company dedicated to advancing gene therapies for rare retinal diseases that affect vision. Utilizing cutting-edge gene-editing techniques and a strong research framework, Opus Genetics seeks to address significant unmet medical needs in ocular health. The company's innovative pipeline, bolstered by ongoing clinical trials and strategic partnerships, positions it favorably within the dynamic healthcare sector, offering substantial growth potential for institutional investors.
Visit Website →Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?